SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-11-292989
Filing Date
2011-11-02
Accepted
2011-11-02 17:09:30
Documents
8
Period of Report
2011-09-24

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d230474d10q.htm 10-Q 310691
2 SECTION 302 CEO AND CFO CERTIFICATION d230474dex31.htm EX-31 10318
3 SECTION 906 CEO AND CFO CERTIFICATION d230474dex32.htm EX-32 3689
  Complete submission text file 0001193125-11-292989.txt   1516757

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT nabi-20110924.xml EX-101.INS 183338
5 XBRL TAXONOMY EXTENSION SCHEMA nabi-20110924.xsd EX-101.SCH 10454
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nabi-20110924_cal.xml EX-101.CAL 34412
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nabi-20110924_lab.xml EX-101.LAB 110882
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nabi-20110924_pre.xml EX-101.PRE 67811
Mailing Address 12276 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12276 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1226
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 111175237
SIC: 2836 Biological Products, (No Diagnostic Substances)